Georgia Bio Executive Committee
Jay Yadav, M.D.
Chairman, Georgia Bio
Founder & CEO, MiRus LLC
Jay S. Yadav, M.D., is the Founder and CEO of MiRus, LLC, an orthopaedic and spine company. He was the founder of CardioMEMS (acquired by St. Jude Medical), Angioguard (acquired by JNJ) and initial investor and director of SMART Therapeutics (acquired by Boston Scientific). Dr. Yadav is a director of several private life sciences and technology companies. He is a Director of Georgia Bio, the Global Center for Medical Innovation (GCMI), the Bio/Med Investor Network, the Southeast Medical Device Association (SEMDA) and Beacon College. He is on the Entrepreneurship Advisory Board of the Yale School of Management.
Dr. Yadav has authored two books, over two hundred publications, and holds over forty patents. He has received numerous honors including the American Heart Association Top Ten Scientific Advances for 2003, Ellis Island Medal of Honor for 2004, Southeast Medical Device Association Entrepreneur of the Year Award for 2010, Phoenix Award for Medical Devices 2011, Association of Telecom Professionals Award 2011, Ernst and Young Entrepreneur of the Year for Healthcare (Southern Region) for 2011, Association for Corporate Growth Deal of the Year 2014 and Georgia Bio Deal of the Year 2014.
Edward J. Schutter
Immediate Past Chairman
President and CEO, Arbor Pharmaceuticals
Edward J. Schutter has more than 25 years of experience in the pharmaceutical industry and is presently serving as President and CEO of Arbor Pharmaceuticals in Atlanta. Prior to this, he was President and COO for Sciele Pharma (a division of Shionogi & Co), also based in Atlanta.
Mr. Schutter spent more than 15 years with Solvay Pharmaceuticals in senior commercial and business development positions based in Marietta, Ga. and Basel, Switzerland. He began his industry career with a small public pharmaceutical company, Reid-Provident Labs, which was eventually acquired by Solvay. Mr. Schutter is a registered pharmacist. He received his B.S. degree in Pharmacy from Mercer University and his MBA from Kennesaw State University.
Heather Mullis, CPA
Partner, Frazier & Deeter
Heather Mullins is an Audit Partner in the Assurance and Advisory Services Practice of Frazier & Deeter. Prior to joining Frazier & Deeter in 2005, Heather spent five years in the audit practice for one of the Big Four accounting firms where she served large public companies and private companies in the middle market. Heather brings over 22 years of experience in public accounting. Her effective problem solving, leadership and communication skills strengthen her ability to provide insights and help her clients reach sound and practical conclusions.
Heather has worked with a variety of institutions, assisting clients with development of policies and procedures and internal controls over financial reporting, as well as performing and managing financial statement reviews and audits and other attestation engagements. Heather works mainly with middle market companies in the private sector, heading up Frazier & Deeter’s Healthcare Practice, as well as focusing on manufacturing and distribution companies, service providers, financial services companies and technology companies.
Heather works closely with Frazier & Deeter’s audit methodology to ensure quality and consistency of procedures throughout the assurance practice. In addition to leading the Healthcare Practice, Heather is a member of the firm’s Technology Industry Group, Manufacturing & Distribution Industry Group and Service Industry Group.
William L. Warren
Partner - IP Practice Group Leader, Sutherland Asbill & Brennan LLP
Bill Warren advises clients on strategic intellectual property issues primarily in the life sciences sector, but also in a number of other industries. The majority of his practice focuses on patents related to biotechnology, medical device and pharmaceutical inventions. Bill prosecutes patents, counsels clients on patent validity and infringement issues and prepares product clearance opinions and development strategies. He also negotiates technology transfer licensing agreements and conducts intellectual property due diligence. Bill protects patents, trademarks and copyrights and, when necessary, participates in litigating intellectual property issues. Bill currently leads Sutherland’s Intellectual Property Practice Group and is chair of the firm’s biotechnology & life sciences team.
2016 Summit Chair
VP, U.S. Corporate Affairs, UCB, Inc.
Patty Fritz has been with UCB for more than 20 years and has made a significant impact through a number of leadership roles, from Regulatory Affairs, to Operational Excellence, to Government Affairs and Policy, Corporate Affairs, and Advocacy.
Patty led the regulatory efforts for UCB’s first product filing - Keppra® (levetiracetam) - and oversaw the FDA approval process for a majority of UCB’s other products including Lortab™ (hydrocodone), Xyzal® (levocetirizine), Cimzia® (certolizumab pegol), and Vimpat® (lacosamide). She managed teams and inspired colleagues as UCB transformed from a primary care company to a specialty biopharma pharmaceutical leader focused on immunological and central nervous system disorders.
In her Corporate Affairs role, Patty has been a champion of several innovative and important projects that spotlight the importance of access and quality care for people living with epilepsy. Collaborating with partners such as the VA Epilepsy Centers of Excellence, PatientsLikeMe®, Emory University, and IBM, Patty has led various initiatives to improve the standard of care for these patients. Her most recent role as External Engagement Lead builds on this experience as Patty works to positively influence the healthcare environment and policy landscape for the benefit of patients and their families.
Patty’s commitment to the success of her colleagues led her to become an Executive Sponsor and a driving force behind the establishment of UCB’s Women in Leadership initiative. She is also active in the community outside of UCB, serving on the board of directors for the Epilepsy Foundation of Georgia, as well as on their Advocacy Committee, bringing her ideas and vision to this active patient organization. Patty also serves on the Board of Directors of Georgia Bio and The Carter Center Board of Councilors. She holds a master’s degree in health care policy and administration from Mercer University, Atlanta, Ga., and a Bachelor of Science degree in management and technology from the University of Maryland, Laurel, Md. Patty is also a graduate of Summers County School of Nursing, Hinton, W.Va.
Patty’s inspirational leadership has made her an effective and admired leader, not just among her colleagues at UCB but within the pharmaceutical industry as a whole, and most importantly with the communities of patients she serves.
Audit & Finance Committee Chair
Senior Manager – Audit & Assurance, Grant Thornton LLP
Biography coming soon.
Russell Medford, MD, Ph.D.
Governance, Nominating & Compensation Committee Chair
Managing Partner, Salutramed Group
Russell M. Medford, MD, PhD, Managing Partner is a senior biotechnology executive with extensive private and public company experience as Chief Executive Officer and Board member of multiple biotechnology and other health related companies, organizations and research institutes. From 1995 to 2009, Dr. Medford served as co-founder, President, CEO and Director of publicly-held AtheroGenics, Inc (Nasdaq: AGIX) and from 2009 to 2012 CEO and Chairman of Salutria Pharmaceuticals, LLC. He was a founding Board Director of publicly-held Inhibitex, Inc. (Nasdaq: INHX) until it was acquired by Bristol-Myers-Squibb in 2012 for $2.5 billion. He has had extensive experience leading companies and organizations engaged in comprehensive therapeutic drug research and development, developing multiple, novel, first-in-man clinical candidates for the treatment of cardiovascular disease, diabetes and arthritis, conducted multiple phase I, II and III clinical studies involving over 400 clinical trial sites in 12 countries, including the US, UK, Canada, South Africa, India, Russia, Eastern Europe and India involving more than 7000 patients, executed multiple strategic partnerships with major pharmaceutical companies including Schering-Plough, Fujisawa and AstraZeneca, as well as building a commercial-scale, manufacturing plant for lead, small-molecule pharmaceutical agents. He has extensive experience in both the private and public financial markets including initial public offerings (IPO) raising over $500 million for corporate, clinical development and research programs. He has served on multiple private company Boards including Transcardiac Therapeutics, Inc., Somatocor, Inc. and EmTech Bio. He is a board-certified physician, an inaugural Fellow of the Council on Basic Cardiovascular Sciences of the American Heart Association, a member of the executive committee and former Chairman of GeorgiaBio, a member of Biotechnology Industry Organization’s (BIO) Board of Directors, Emerging Companies Section Governing Board and Health Science Governing Board, Co-Chairman of BIO’s Bioethics Committee and served as Chairman of the BIO's 2009 International Convention Steering Committee. Dr. Medford is a past member of the Advisory Council of the National Heart, Lung and Blood Institute and currently serves on the Board of Trustees of the National Health Museum and Chairman of the External Advisory Board for the Petit Institute of Bioscience and Bioengineering of the Georgia Institute of Technology. He has received numerous awards including the Ernst and Young Entrepreneur of the Year Award (Southeast), the Biomedical Industry Growth Award (Georgia Bio), CATALYST Magazine's Top 50 Entrepreneurs and the SCRIPP Best Partnership Alliance (London). Dr. Medford also serves as Chairman of Artetude Gallery, Inc., a private, North Carolina contemporary fine art company based in Asheville. Dr. Medford was an Associate Professor of Medicine, Director of Molecular Cardiology and Adjunct Clinical Professor of Medicine at the Emory University School of Medicine where he founded Atherogenics, Inc. He received a B.A. from Cornell University, and a M.D. with Distinction and a Ph.D. in Molecular and Cell Biology from the Albert Einstein College of Medicine, completing his residency and cardiology fellowship at Harvard’s Beth Israel and Brigham and Women’s Hospitals where he also served on the faculty of Medicine. He publishes widely and holds over 16 U.S. and international patents.
Holly Bates Snow
Policy & Advocacy Committee Chair
State Government Affairs Sr. Manager, South, Amgen
Holly joined Amgen in 2013 and is responsible for representing Amgen’s interests before state legislative, regulatory and executive branches in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, and Tennessee.
Prior to joining Amgen, Holly was Vice President for a leading health system in Georgia, Piedmont Healthcare for eight years. This system included 5 acute care hospitals, more than 10,000 employees, and some 1000 physicians (350 of whom were employed). . In this role, Holly was responsible for overseeing all aspects of federal, state, and local government relations for the system, which included policy development, lobbying, regulatory representation before local, state, and U.S. officials. Her other responsibilities included coalition building with other hospitals and various organizations such as the Georgia Hospital Association, Georgia Chamber of Commerce, Medical Association of Georgia, and patient groups.
Prior to Piedmont, Holly was Vice President of Government Affairs for the Georgia Hospital Association where she worked for 15 years. She developed and executed strategic plans and lobbied interests of for-profit, non-profit, and government acute care, rehab, and substance abuse hospitals before the U.S. Congress, Georgia General Assembly, governor, appointed and elected agencies. She also worked with business, civic and healthcare organizations and coalitions to influence policy positions to support and enhance hospital initiatives.
She started her career in public relations and government affairs with a family owned firm in Atlanta where she served as Vice President for 10 years. In this capacity, she worked closely with the media, wrote speeches, developed and executed media/and public relations campaigns. Additionally, she represented various clients before the Georgia General Assembly including Morehouse School of Medicine and Grady Hospital (the state’s largest public/indigent care facility),
Currently, Holly services as Vice Chair of the PhRMA Task Force in GA, Chair of the Georgia Bio government affairs committee, and Board of Directors member for BIO FL where she also serves on the government affairs committee.
Holly was graduated with Bachelor of Arts degrees in communications and political science from Tulane University and Newcomb College in New Orleans. She is an avid exercise and sports enthusiast as well as an apiarist when she is not trying to keep her youngest son out of jail and her oldest son in college.
Jamie L. Graham
2015-2016 Georgia BioEd Institute Chair
Partner, Kilpatrick Townsend & Stockton
Jamie Graham focuses her practice on intellectual property issues involving biological and chemical technologies. Ms. Graham conducts domestic and foreign biological and chemical patent prosecution, particularly in the areas of biotechnology, diagnostics, isolation and purification methodology, immunology and pharmaceuticals. She renders patentability, patent validity and freedom-to-operate opinions; performs intellectual property due diligence; and provides advice to clients regarding various aspects of intellectual property, including inventorship determinations, licensing, transactions, pre-litigation and litigation strategies. Ms. Graham has provided intellectual property advice and services to universities, large corporations, small start-up companies and government entities and has been awarded federal and state contracts for patent legal services. Ms. Graham is the Co-Chair of the firm's Health and Life Sciences team.
Ms. Graham has been a registered U.S. Patent Attorney since 1986. Prior to joining the firm, she served as in-house patent counsel for a pharmaceutical company. She has conducted enzyme isolation and characterization research at Sloan-Kettering Institute for Cancer Research and cardiac and allergy drug dispositon/metabolism research at Boehringer Ingelheim Ltd. Ms. Graham also performed graduate research in neuroimmunology and virology (HIV research conducted at the Centers for Disease Control and Prevention). She has been an adjunct professor of Intellectual Property Law at Emory University.
Ms. Graham was listed in The Best Lawyers of America® for Biotechnology and Intellectual Property in 2015 and each of the 14 years immediately preceding. She was also named a 2012 and 2013 "Atlanta Lawyer of the Year" in the area of Biotechnology Law by The Best Lawyers in America®. Ms. Graham was listed in The International Who’s Who of Business Lawyers for Patents in 2013 and in The International Who's Who of Patent Lawyers in 2011. She was recognized in 2015 and the six years immediately preceding as a Georgia "Super Lawyer" in the area of Intellectual Property by Super Lawyers magazine. Ms. Graham has been recognized as one of Georgia Trend's 2012 “Legal Elite” for Intellectual Property Law. She was honored by the Georgia Chapter of the Huntington's Disease Society of America at its 2012 Celebration of Hope Gala. Ms. Graham is a recipient of the prestigious 2015 Georgia Bio Community Award for her significant contributions to Georgia's life sciences industry. She is AV® rated by Martindale-Hubbell.*
*CV, BV, and AV are registered certification marks of Reed Elsevier Properties Inc., used in accordance with the Martindale-Hubbell certification procedure's standards and policies.